AbstractTakayasu arteritis (TAK) is a large-sized vessel vasculitis that involves the aorta and its major branches. The overproduction of interleukin-6 (IL-6) has been proved to play a major role in the pathogenesis of TAK. The following case report describes a 21-year-old woman with refractory TAK, treated with tocilizumab – IL-6 receptor antibody. As a result of the treatment, the clinical manifestations and the abnormal laboratory fi ndings were improved, which allowed the tapering of the glucocorticoids without a consequent relapse of the disease for a follow-up period of 2 years. The results suggest that inhibition of the IL-6 pathway may be a possible treatment option for patients with refractory TAK.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.